Growth Metrics

Edwards Lifesciences (EW) Non-Current Debt (2016 - 2026)

Edwards Lifesciences has reported Non-Current Debt over the past 17 years, most recently at $598.3 million for Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.1% year-over-year to $598.3 million; the TTM value through Dec 2025 reached $598.3 million, changed 0.1%, while the annual FY2025 figure was $598.3 million, 0.1% changed from the prior year.
  • Non-Current Debt for Q4 2025 was $598.3 million at Edwards Lifesciences, roughly flat from $598.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $598.3 million in Q4 2025 and troughed at $595.2 million in Q1 2021.
  • A 5-year average of $596.8 million and a median of $596.8 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: rose 0.12% in 2021 and later rose 0.1% in 2025.
  • Year by year, Non-Current Debt stood at $595.7 million in 2021, then increased by 0.1% to $596.3 million in 2022, then grew by 0.12% to $597.0 million in 2023, then rose by 0.12% to $597.7 million in 2024, then grew by 0.1% to $598.3 million in 2025.
  • Business Quant data shows Non-Current Debt for EW at $598.3 million in Q4 2025, $598.2 million in Q3 2025, and $598.0 million in Q2 2025.